Role of Radiation Therapy in a Patient with Primary Pancreatic Lymphoma

2005 ◽  
Vol 6 (2) ◽  
pp. 143-145 ◽  
Author(s):  
Karen H. Shahar ◽  
L. Steven Carpenter ◽  
Jeffrey Jorgensen ◽  
Luan Truong ◽  
Kelty Baker ◽  
...  
2010 ◽  
Vol 4 (1) ◽  
pp. 104-110 ◽  
Author(s):  
Hiroki Sugishita ◽  
Yuji Watanabe ◽  
Yuji Yamamoto ◽  
Motohira Yoshida ◽  
Koichi Sato ◽  
...  

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 303-303
Author(s):  
M. V. Mishra ◽  
S. W. Keith ◽  
X. Shen ◽  
T. Biswas

303 Background: Primary pancreatic lymphoma (PPL) is a rare disease, accounting for only 0.5% of all pancreatic masses. The clinical presentation of PPL is similar to that of pancreatic adenocarcinoma and the two are difficult to distinguish radiographically. A paucity of literature exists on the epidemiology and outcomes of PPL. Given the limited case reports published on PPL, a comparison of the different treatment modalities has previously not been possible. Here, we present a series of 523 cases of PPL obtained from the Surveillance, Epidemiology, and End Results (SEER) database to investigate the tumor characteristics and compare the different treatment modalities. Methods: Patients diagnosed with a primary pancreatic lymphoma from 1973-2007 were identified. Data on patient and tumor characteristics as well as initial treatment with surgery or radiation was extracted. Chemotherapy information is not available through SEER. Overall survival was calculated using the Kaplan-Meier method. A multivariate analysis was performed to determine independent prognostic factors predicting for survival using a Cox proportional hazards model. Results: Fifty-eight percent of patients identified were male. The median age range at diagnosis was 65-69 years (range, 10-14 years – greater than 85 years). The most common histologic subtype in the present series was diffuse large B-cell lymphoma (DLBCL), which accounted for 71% of all patients. The 5-year overall survival for the group was 47%. Multivariate analysis indicates that age >60 and a marital status of single were predictive of a decreased cause-specific and overall-survival specific survival (p<0.05). Radiation therapy, but not surgery, was predictive of an improved overall survival (p<0.05). Conclusions: PPL is a rare form of extra-nodal NHLs of the GI tract. Adjuvant radiation therapy for patients with a PPL should be strongly considered and a surgical treatment should be avoided if an early diagnosis is established. A prospective study evaluating this patient population will be difficult given the rarity PPL. We hope that this case series will provide a context in evaluating and treating patients with PPL. No significant financial relationships to disclose.


1984 ◽  
Vol 17 (1) ◽  
pp. 227-235
Author(s):  
Leslie E. Botnick ◽  
Christopher M. Rose ◽  
Izhak Goldberg ◽  
Abraham Recht

2003 ◽  
Vol 13 (2) ◽  
pp. 109-120 ◽  
Author(s):  
Terence Roberts ◽  
Mack Roach

2021 ◽  
Vol 23 (1) ◽  
Author(s):  
Ammoren Dohm ◽  
Roberto Diaz ◽  
Ronica H. Nanda

Author(s):  
Sean Platt ◽  
Diva R. Salomao ◽  
Jose Pulido

Abstract Introduction Little has been published about the choroidal vascular changes that occur years after radiation exposure. The aim of this study was to review the histological changes observed in the choroidal vasculature following radiotherapy for uveal melanoma. Methods Records from a single institution were retrospectively reviewed from June 7, 2007 to June 7, 2017; 101 patients with a diagnosis of uveal melanoma that underwent enucleation had their records reviewed. Out of these, a total of 26 eyes had undergone plaque brachytherapy prior to enucleation, which had been performed at a mean time of 7.2 years (range from 0 years to 30 years) after the initial plaque placement. A histopathologic analysis was conducted on all 26 eyes with special emphasis on the choroidal changes. Of these 26 eyes, 18 demonstrated evidence of radiation-induced vasculopathy. Results Of the 18 eyes, 10/18 (55%) had radiation retinopathy and 16/18 (89%) had radiation choroidal vasculopathy. One patient had a phthisical eye, and the choroid could not be evaluated because the characteristics of the vasculature could not be determined. Nine cases had vitreous hemorrhage (50%), all cases had radiation retinopathy, and 8/9 (89%) had radiation choroidopathy. Of the 16 cases with radiation choroidal vasculopathy, 3/16 (19%) had only intratumoral radiation choroidal vasculopathy, 3/16 (19%) had only extratumoral radiation choroidal vasculopathy, and, thus, 10/16 (32%) had both intratumoral and extratumoral radiation choroidal vasculopathy. In patients with radiation choroidal vasculopathy, 2/16 (13%) had hyalinization of the choroidal vessels. Another 3/16 (19%) cases with radiation choroidal vasculopathy had ectatic vessels. The other 11/16 (68%) had evidence of both hyalinization of the choroidal vessels as well as ectatic vessels in the choroid. Histological evidence of radiation retinopathy and choroidopathy were seen in 69% of eyes enucleated after receiving radiation therapy, which, in some cases, also had vitreous hemorrhage. Polypoidal choroidal vasculopathy, choroidal neovascularization, and retinal choroidal anastomoses (RAP-type lesions) were seen in 12 of the 16 eyes (75%). Discussion/Conclusion Irradiation of malignant tumors of the eye causes not only radiation retinopathy but also radiation choroidopathy. The role of radiation choroidopathy in the subsequent visual loss following radiotherapy and the role of anti-VEGF therapy needs to be recognized and distinguished from radiation retinopathy. Our data adds to the prior limited knowledge that radiation affects the choroid and can induce specific phenotypes similar to the clinical spectrum of CNV, PCV, and RAP.


2016 ◽  
Vol 27 (suppl_9) ◽  
Author(s):  
S.H. Lee ◽  
K.C. Lee ◽  
K. Sung ◽  
E.Y. Choi ◽  
J.B. Bae ◽  
...  

2016 ◽  
Vol 95 (2) ◽  
pp. 617-631 ◽  
Author(s):  
Vivek Verma ◽  
Frank Vicini ◽  
Rahul D. Tendulkar ◽  
Atif J. Khan ◽  
Jessica Wobb ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document